retatrutide phase 2 results 2024 2025 press release 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending June 8, 2026: Reckless physicians

a natural complete synbiotic with prebiotic fiber, inulin, and prebiotics

Set yourself up for success with this expert advice.

Initially designed for managing type 2 diabetes, these GLP-1 receptor agonists have proven so effective at curbing appetite that theyre now being prescribed off-label for weight loss

The key to future success will be adapting product selections and marketing to line up with the new health-focused mindset of this growing group of shoppers...

SALT LAKE CITY, Utah, March 12, 2026 (Bill's Marketplace/Gephardt Daily)-- A major shift is underway in the weight-loss medication market as Wegovy becomes the first pill form of semaglutide available in the United States

Rybelsus is an innovative GLP-1 receptor agonist that helps support weight management through science-backed mechanisms